Found: 39
Select item for more details and to access through your institution.
Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 1066, doi. 10.1007/s10637-022-01269-9
- By:
- Publication type:
- Article
Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer.
- Published in:
- Cancer Imaging, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s40644-023-00538-x
- By:
- Publication type:
- Article
Elderly-onset hereditary pulmonary alveolar proteinosis and its cytokine profile.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. N.PAG, doi. 10.3389/fonc.2021.610952
- By:
- Publication type:
- Article
Establishing a whole blood CD4<sup>+</sup> T cell immunity measurement to predict response to anti-PD-1.
- Published in:
- BMC Cancer, 2022, v. 22, n. 1, p. 1, doi. 10.1186/s12885-022-10445-2
- By:
- Publication type:
- Article
Establishing a whole blood CD4<sup>+</sup> T cell immunity measurement to predict response to anti-PD-1.
- Published in:
- BMC Cancer, 2022, v. 22, n. 1, p. 1, doi. 10.1186/s12885-022-10445-2
- By:
- Publication type:
- Article
Efficacy and Safety of Anti-Programed Death-1 Blockade in Previously Treated Large-Cell Neuroendocrine Carcinoma.
- Published in:
- Chemotherapy (0009-3157), 2021, v. 66, n. 3, p. 65, doi. 10.1159/000514841
- By:
- Publication type:
- Article
Clinical Utility of Inflammatory and Nutritious Index as Therapeutic Prediction of Nivolumab plus Ipilimumab in Advanced Non-Small Cell Lung Cancer.
- Published in:
- Oncology, 2024, v. 102, n. 3, p. 271, doi. 10.1159/000534169
- By:
- Publication type:
- Article
Metachronous lesions in the orbit, retroperitoneum, and pleura of mucosa‐associated lymphoid tissue lymphoma: A case report.
- Published in:
- Cancer Reports, 2022, v. 5, n. 10, p. 1, doi. 10.1002/cnr2.1689
- By:
- Publication type:
- Article
Clinical impact of inflammatory and nutrition index based on metabolic tumor activity in non‑small cell lung cancer treated with immunotherapy.
- Published in:
- Oncology Letters, 2024, v. 27, n. 3, p. N.PAG, doi. 10.3892/ol.2024.14243
- By:
- Publication type:
- Article
Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer.
- Published in:
- Oncology Letters, 2023, v. 25, n. 3, p. N.PAG, doi. 10.3892/ol.2023.13696
- By:
- Publication type:
- Article
Clinical significance of antinuclear antibody as prognostic marker for first-line pembrolizumab in advanced non-small cell lung cancer.
- Published in:
- International Journal of Clinical Oncology, 2024, v. 29, n. 2, p. 124, doi. 10.1007/s10147-023-02445-4
- By:
- Publication type:
- Article
Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2022.1080729
- By:
- Publication type:
- Article
Clinicopathological impact of VEGFR2 and VEGF‐C in patients with EGFR‐major mutant NSCLC receiving osimertinib.
- Published in:
- Thoracic Cancer, 2023, v. 14, n. 29, p. 2950, doi. 10.1111/1759-7714.15082
- By:
- Publication type:
- Article
Post‐progression survival after atezolizumab plus carboplatin and etoposide as first‐line chemotherapy in small cell lung cancer has a significant impact on overall survival.
- Published in:
- Thoracic Cancer, 2022, v. 13, n. 19, p. 2776, doi. 10.1111/1759-7714.14621
- By:
- Publication type:
- Article
Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non‐small cell lung cancer.
- Published in:
- Thoracic Cancer, 2022, v. 13, n. 10, p. 1479, doi. 10.1111/1759-7714.14417
- By:
- Publication type:
- Article
Real‐world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive‐disease small‐cell lung cancer.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 1, p. 73, doi. 10.1002/cam4.4938
- By:
- Publication type:
- Article
Tumor metabolic volume by <sup>18</sup>F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%.
- Published in:
- Scientific Reports, 2020, v. 10, n. 1, p. N.PAG, doi. 10.1038/s41598-020-71735-y
- By:
- Publication type:
- Article
Clinical impact of post‐progression survival on overall survival in patients receiving nivolumab monotherapy as a second‐line treatment for advanced non‐small cell lung cancer.
- Published in:
- Thoracic Cancer, 2021, v. 12, n. 8, p. 1171, doi. 10.1111/1759-7714.13886
- By:
- Publication type:
- Article
Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure.
- Published in:
- Thoracic Cancer, 2021, v. 12, n. 6, p. 864, doi. 10.1111/1759-7714.13864
- By:
- Publication type:
- Article
Pre‐existing interstitial lung disease does not affect prognosis in non‐small cell lung cancer patients with PD‐L1 expression ≥50% on first‐line pembrolizumab.
- Published in:
- Thoracic Cancer, 2021, v. 12, n. 3, p. 304, doi. 10.1111/1759-7714.13725
- By:
- Publication type:
- Article
Primary thymic adenocarcinoma with an aggressive clinical course: An autopsy case showing signet ring cell‐like features.
- Published in:
- Thoracic Cancer, 2020, v. 11, n. 12, p. 3609, doi. 10.1111/1759-7714.13700
- By:
- Publication type:
- Article
Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events.
- Published in:
- Thoracic Cancer, 2020, v. 11, n. 5, p. 1280, doi. 10.1111/1759-7714.13394
- By:
- Publication type:
- Article
Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non‐small cell lung cancer harboring EGFR mutation.
- Published in:
- Thoracic Cancer, 2020, v. 11, n. 4, p. 1045, doi. 10.1111/1759-7714.13363
- By:
- Publication type:
- Article
Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab.
- Published in:
- Thoracic Cancer, 2019, v. 10, n. 4, p. 992, doi. 10.1111/1759-7714.13044
- By:
- Publication type:
- Article
Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer.
- Published in:
- Thoracic Cancer, 2019, v. 10, n. 4, p. 975, doi. 10.1111/1759-7714.13039
- By:
- Publication type:
- Article
Clinical significance of primary prophylactic pegylated‐granulocyte‐colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non‐small cell lung cancer.
- Published in:
- Thoracic Cancer, 2019, v. 10, n. 4, p. 1005, doi. 10.1111/1759-7714.13022
- By:
- Publication type:
- Article
Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients.
- Published in:
- Thoracic Cancer, 2019, v. 10, n. 4, p. 775, doi. 10.1111/1759-7714.12998
- By:
- Publication type:
- Article
Treatments and outcomes of advanced/ recurrent non-small cell lung cancer harboring the EGFR T790M mutation: a retrospective observational study of 141 patients in Japan.
- Published in:
- Japanese Journal of Clinical Oncology, 2016, v. 46, n. 12, p. 1135, doi. 10.1093/jjco/hyw124
- By:
- Publication type:
- Article
Correction to: Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation.
- Published in:
- 2020
- By:
- Publication type:
- corrected article
Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Therapeutic Resistance in G-CSF Producing Lung Cancer With EGFR Mutation.
- Published in:
- Cancer Diagnosis & Prognosis, 2024, v. 4, n. 4, p. 529, doi. 10.21873/cdp.10359
- By:
- Publication type:
- Article
Severe Thrombocytopenia Associated With Pembrolizumab in Patients With Non-small Cell Lung Cancer (NSCLC): A Case Report and Literature Review.
- Published in:
- In Vivo, 2020, v. 34, n. 2, p. 877, doi. 10.21873/invivo.11852
- By:
- Publication type:
- Article
Effect of Systemic Steroid Use for Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Receiving PD-1 Blockade Drugs.
- Published in:
- Journal of Clinical Medicine, 2021, v. 10, n. 16, p. 3744, doi. 10.3390/jcm10163744
- By:
- Publication type:
- Article
Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer.
- Published in:
- Journal of Clinical Medicine, 2020, v. 9, n. 3, p. 725, doi. 10.3390/jcm9030725
- By:
- Publication type:
- Article
Prospective assessment using <sup>18</sup>F-FDG PET/CT as a novel predictor for early response to PD-1 blockade in non-small-cell lung cancer.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-15964-3
- By:
- Publication type:
- Article
Potential of VEGFR2 expression as a predictive marker of PD-1 blockade in patients with advanced NSCLC.
- Published in:
- Oncology Reports, 2022, v. 48, n. 6, p. N.PAG, doi. 10.3892/or.2022.8429
- By:
- Publication type:
- Article
Combination of immune check inhibitor and immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis: A case report.
- Published in:
- 2021
- By:
- Publication type:
- Case Study